MTNB

The company's core asset is its proprietary Lipid NanoCrystal (LNC) platform, a delivery technology designed to enable the oral administration of medicines that are otherwise difficult to absorb or that require injection. This platform is being applied to a range of potential treatments, including small molecule drugs, nucleic acids, and proteins.

Matinas is advancing a pipeline of product candidates built on this technology. Its lead candidate, MAT2203, is an oral formulation of the antifungal drug amphotericin B currently in clinical development. It is being studied for serious fungal infections like aspergillosis and for preventing fungal infections in immunocompromised patients. The company is also developing MAT2501, an oral formulation of the antibiotic amikacin. As a clinical-stage company, Matinas does not currently generate revenue from product sales and its future success depends on the outcome of clinical trials and regulatory processes.